These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19847629)

  • 1. Non-compartmental estimation of pharmacokinetic parameters in serial sampling designs.
    Wolfsegger MJ; Jaki T
    J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):479-94. PubMed ID: 19847629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confidence intervals for ratios of AUCs in the case of serial sampling: a comparison of seven methods.
    Jaki T; Wolfsegger MJ; Ploner M
    Pharm Stat; 2009; 8(1):12-24. PubMed ID: 18407562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing bioequivalence in serial sacrifice designs.
    Wolfsegger MJ
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):103-13. PubMed ID: 17053981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of AUC from 0 to Infinity in Serial Sacrifice Designs.
    Wolfsegger MJ; Jaki T
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):757-66. PubMed ID: 16328101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of new measures of nonlinearity to parameter estimation and simulations in individual pharmacokinetic analyses.
    Khinkis L; Crotzer M
    J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):43-52. PubMed ID: 30607795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing bioequivalence in complete and incomplete data designs using AUCs.
    Jaki T; Wolfsegger MJ; Lawo JP
    J Biopharm Stat; 2010 Jul; 20(4):803-20. PubMed ID: 20496207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of pseudo-profiles in organ pharmacokinetics and toxicokinetics.
    Mager H; Göller G
    Stat Med; 1995 May 15-30; 14(9-10):1009-24. PubMed ID: 7569497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.
    Knights J; Rohatagi S
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):627-37. PubMed ID: 26209956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Model-Based Bioequivalence Statistical Approaches for Pharmacokinetic Studies with Sparse Sampling.
    Loingeville F; Bertrand J; Nguyen TT; Sharan S; Feng K; Sun W; Han J; Grosser S; Zhao L; Fang L; Möllenhoff K; Dette H; Mentré F
    AAPS J; 2020 Oct; 22(6):141. PubMed ID: 33125589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative pharmacokinetic analysis based on nonlinear mixed effect model].
    Li LJ; Li XX; Xu L; Lü YH; Chen JC; Zheng QS
    Yao Xue Xue Bao; 2011 Apr; 46(4):447-53. PubMed ID: 21751499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimisation of sampling windows design for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Pharmacokinet Pharmacodyn; 2008 Aug; 35(4):465-82. PubMed ID: 18780163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies.
    Ette EI; Howie CA; Kelman AW; Whiting B
    Pharm Res; 1995 May; 12(5):729-37. PubMed ID: 7479560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and inference for 3-stage bioequivalence testing with serial sampling data.
    Yan F; Zhu H; Liu J; Jiang L; Huang X
    Pharm Stat; 2018 Sep; 17(5):458-476. PubMed ID: 29726096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of two sparse sampling population pharmacokinetic approaches for the estimation of pharmacokinetic parameters in children.
    Mahmood I; Tammara V
    Int J Clin Pharmacol Ther; 2004 Apr; 42(4):240-5. PubMed ID: 15124982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size calculations based on generalized estimating equations for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L; Graham G
    J Biopharm Stat; 2006; 16(2):135-50. PubMed ID: 16584063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profile likelihood-based confidence intervals using Monte Carlo integration for population pharmacokinetic parameters.
    Funatogawa T; Funatogawa I; Yafune A
    J Biopharm Stat; 2006; 16(2):193-205. PubMed ID: 16584067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of random and fixed (optimal) sampling approach on the Bayesian estimation of clearance.
    Mahmood I
    Int J Clin Pharmacol Ther; 2003 Sep; 41(9):392-6. PubMed ID: 14526763
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.